Palliative treatment of germ cell cancer

Christoph Oing; Patrizia Giannatempo; Friedemann Honecker; Karin Oechsle; Carsten Bokemeyer; Jörg Beyer

doi:10.1016/j.ctrv.2018.10.007

Palliative treatment of germ cell cancer

Standard

Palliative treatment of germ cell cancer. / Oing, Christoph; Giannatempo, Patrizia; Honecker, Friedemann; Oechsle, Karin ; Bokemeyer, Carsten; Beyer, Jörg.

in: CANCER TREAT REV, Jahrgang 71, 12.2018, S. 102-107.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Oing, C, Giannatempo, P, Honecker, F, Oechsle, K , Bokemeyer, C & Beyer, J 2018, 'Palliative treatment of germ cell cancer', CANCER TREAT REV, Jg. 71, S. 102-107. https://doi.org/10.1016/j.ctrv.2018.10.007

APA

Oing, C., Giannatempo, P., Honecker, F., Oechsle, K., Bokemeyer, C., & Beyer, J. (2018). Palliative treatment of germ cell cancer. CANCER TREAT REV, 71, 102-107. https://doi.org/10.1016/j.ctrv.2018.10.007

Vancouver

Oing C, Giannatempo P, Honecker F, Oechsle K , Bokemeyer C, Beyer J. Palliative treatment of germ cell cancer. CANCER TREAT REV. 2018 Dez;71:102-107. https://doi.org/10.1016/j.ctrv.2018.10.007

Bibtex

@article{f9d69d87d3af48599db4670bf8744966,

title = "Palliative treatment of germ cell cancer",

abstract = "Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic.",

keywords = "Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bone Neoplasms/secondary, Brain Neoplasms/secondary, Humans, Immunotherapy/methods, Molecular Targeted Therapy/methods, Neoplasms, Germ Cell and Embryonal/pathology, Palliative Care/methods, Peripheral Nervous System Diseases/etiology, Psychosocial Support Systems",

author = "Christoph Oing and Patrizia Giannatempo and Friedemann Honecker and Karin Oechsle and Carsten Bokemeyer and J{\"o}rg Beyer",

year = "2018",

month = dec,

doi = "10.1016/j.ctrv.2018.10.007",

language = "English",

volume = "71",

pages = "102--107",

journal = "CANCER TREAT REV",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

RIS

TY - JOUR

T1 - Palliative treatment of germ cell cancer

AU - Oing, Christoph

AU - Giannatempo, Patrizia

AU - Honecker, Friedemann

AU - Oechsle, Karin

AU - Bokemeyer, Carsten

AU - Beyer, Jörg

PY - 2018/12

Y1 - 2018/12

N2 - Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic.

AB - Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic.

KW - Antineoplastic Agents/therapeutic use

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Bone Neoplasms/secondary

KW - Brain Neoplasms/secondary

KW - Humans

KW - Immunotherapy/methods

KW - Molecular Targeted Therapy/methods

KW - Neoplasms, Germ Cell and Embryonal/pathology

KW - Palliative Care/methods

KW - Peripheral Nervous System Diseases/etiology

KW - Psychosocial Support Systems

U2 - 10.1016/j.ctrv.2018.10.007

DO - 10.1016/j.ctrv.2018.10.007

M3 - SCORING: Review article

C2 - 30415106

VL - 71

SP - 102

EP - 107

JO - CANCER TREAT REV

JF - CANCER TREAT REV

SN - 0305-7372

ER -